Marilyn Albert, PhD, is Professor of Neurology and Director of the Division of Cognitive Neuroscience in the Department of the Neurology at the Johns Hopkins University School of Medicine. She is also the Director of the Johns Hopkins Alzheimer’s Disease Research Center.

Her research focuses on understanding the cognitive and brain changes in aging and neurodegenerative disorders such as AD. Dr. Albert’s research aims to identify the relationship between biomarkers based on imaging, cerebrospinal fluid, blood and genetics to cognitive changes and the early diagnosis of AD. Her research was the first to show the characteristic feature of delayed recall in AD.

Dr. Albert’s work on the examination of risk and protective factors in progression from normal cognition to mild cognitive impairment incorporates the important concept of cognitive reserve. More recently her work has combined longitudinal studies with biomarkers and cognitive test scores to characterize the progression across the AD continuum.

Abhay Moghekar is an Associate Professor of Neurology at the Johns Hopkins School of Medicine. He is Clinical Director of the CSF Disorders Program at Johns Hopkins Hospital and Leader of the Biospecimen Core for the BIOCARD study. His research is focused on examining measures in cerebrospinal fluid that are predictors of cognitive decline and may serve as targets for drug development for the treatment of Alzheimer’s disease.

Marilyn Albert, PhD, is Professor of Neurology and Director of the Division of Cognitive Neuroscience in the Department of the Neurology at the Johns Hopkins University School of Medicine. She is also the Director of the Johns Hopkins Alzheimer’s Disease Research Center.

Her research focuses on understanding the cognitive and brain changes in aging and neurodegenerative disorders such as AD. Dr. Albert’s research aims to identify the relationship between biomarkers based on imaging, cerebrospinal fluid, blood and genetics to cognitive changes and the early diagnosis of AD. Her research was the first to show the characteristic feature of delayed recall in AD.

Dr. Albert’s work on the examination of risk and protective factors in progression from normal cognition to mild cognitive impairment incorporates the important concept of cognitive reserve. More recently her work has combined longitudinal studies with biomarkers and cognitive test scores to characterize the progression across the AD continuum.

Arnold Bakker is Director, Psychiatry Neuroimaging Core and 
Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. His research focuses on the cognitive neuroscience of human memory. He studies the neural mechanisms underlying normal memory function and impaired memory function in aging and disease using neuropsychological assessment, experimental behavioral assessment and particularly advanced neuroimaging methods, including structural and functional magnetic resonance imaging, diffusion tensor imaging, and magnetic resonance spectroscopy.

Marilyn Albert, PhD, is Professor of Neurology and Director of the Division of Cognitive Neuroscience in the Department of the Neurology at the Johns Hopkins University School of Medicine. She is also the Director of the Johns Hopkins Alzheimer’s Disease Research Center.

Her research focuses on understanding the cognitive and brain changes in aging and neurodegenerative disorders such as AD. Dr. Albert’s research aims to identify the relationship between biomarkers based on imaging, cerebrospinal fluid, blood and genetics to cognitive changes and the early diagnosis of AD. Her research was the first to show the characteristic feature of delayed recall in AD.

Dr. Albert’s work on the examination of risk and protective factors in progression from normal cognition to mild cognitive impairment incorporates the important concept of cognitive reserve. More recently her work has combined longitudinal studies with biomarkers and cognitive test scores to characterize the progression across the AD continuum.

Abhay Moghekar is an Associate Professor of Neurology at the Johns Hopkins School of Medicine. He is Clinical Director of the CSF Disorders Program at Johns Hopkins Hospital and Leader of the Biospecimen Core for the BIOCARD study. His research is focused on examining measures in cerebrospinal fluid that are predictors of cognitive decline and may serve as targets for drug development for the treatment of Alzheimer’s disease.

Marilyn Albert, PhD, is Professor of Neurology and Director of the Division of Cognitive Neuroscience in the Department of the Neurology at the Johns Hopkins University School of Medicine. She is also the Director of the Johns Hopkins Alzheimer’s Disease Research Center.

Her research focuses on understanding the cognitive and brain changes in aging and neurodegenerative disorders such as AD. Dr. Albert’s research aims to identify the relationship between biomarkers based on imaging, cerebrospinal fluid, blood and genetics to cognitive changes and the early diagnosis of AD. Her research was the first to show the characteristic feature of delayed recall in AD.

Dr. Albert’s work on the examination of risk and protective factors in progression from normal cognition to mild cognitive impairment incorporates the important concept of cognitive reserve. More recently her work has combined longitudinal studies with biomarkers and cognitive test scores to characterize the progression across the AD continuum.

Bonnielin Swenor is the Director of the Johns Hopkins Disability Health Research Center and an associate professor of ophthalmology at the Wilmer Eye Institute. She is also an associate professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, as well as a core faculty member at the Johns Hopkins Center on Aging and Health.

Dr. Swenor’s research aims to improve the health of people with disabilities, including visual impairments and is fueled by her personal experience with a visual disability. To achieve this, Dr. Swenor and her group have concentrated on three interrelated areas:

Vision and Aging: This research aims to improve the health and well-being of individuals with visual impairments across the lifespan, with a focus on older adults.
Access to Care: This area of research focuses on identifying health care disparities and improving healthcare utilization, quality, and access for people with disabilities.

Disability Inclusion: By identifying and addressing barriers for people with visual impairments and other disabilities in the biomedical workforce and across society, Dr. Swenor is working to increase disability inclusion.

Dr. Swenor and her team are now expanding on this research framework to more broadly examine Disability Health. This area of research examines disability – including visual impairment – as a health disparity population, and uses an interdisciplinary and collaborative approach to establish the evidence needed to design effective policies and programs that will reduce disability inequities. The overarching goals of this research are to maximize health, equity, and participation for people with all types of disabilities.

Dr. Swenor received her master of public health and doctorate degrees in epidemiology from the Johns Hopkins Bloomberg School of Public Health. She completed a postdoctoral research fellowship at the National Institute on Aging prior to joining the Wilmer faculty. She holds a joint appointment with the Department of Epidemiology at the Bloomberg School of Public Health.

Marilyn Albert, PhD, is Professor of Neurology and Director of the Division of Cognitive Neuroscience in the Department of the Neurology at the Johns Hopkins University School of Medicine. She is also the Director of the Johns Hopkins Alzheimer’s Disease Research Center.

Her research focuses on understanding the cognitive and brain changes in aging and neurodegenerative disorders such as AD. Dr. Albert’s research aims to identify the relationship between biomarkers based on imaging, cerebrospinal fluid, blood and genetics to cognitive changes and the early diagnosis of AD. Her research was the first to show the characteristic feature of delayed recall in AD.

Dr. Albert’s work on the examination of risk and protective factors in progression from normal cognition to mild cognitive impairment incorporates the important concept of cognitive reserve. More recently her work has combined longitudinal studies with biomarkers and cognitive test scores to characterize the progression across the AD continuum.

Paul B. Rosenberg, MD, is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine His research focuses on developing new treatments for Alzheimer’s Disease (AD) especially neuropsychiatric symptoms and relevant biomarkers including sleep and circadian rhythm.

Dr. Rosenberg is a 2008 Paul Beeson Scholar, chaired the NIA-N SRG at the National Institute on Aging, and served on the FDA Advisory Committee for Peripheral and Central Nervous System Drugs. He trained in Adult Psychiatry at Tufts University/New England Medical Center and Geriatric Psychiatry at Mclean Hospital.